

**TEST CHANGE** 

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by CBA-IFA with Reflex to Titer, Serum

Effective Date: August 21, 2023

3001260, AMPA SER

| Specimen Requirements:        |  |
|-------------------------------|--|
| Patient Preparation:          |  |
| Collect:                      | Serum <u>separator tube</u> Separator Tube (SST) or <u>plain red</u> Plain Red.  |
| Specimen Preparation:         | Transfer 1 mL serum to an ARUP <u>standard transport</u> <u>tube.</u> Standard Transport Tube. (Min: 0.15 mL)  |
| Transport Temperature:        | Refrigerated.  |
| Unacceptable Conditions:      | Hemolyzed, contaminated, or severely lipemic specimens.  |
| Remarks:                      |  |
| Stability:                    | Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month  |
| Methodology:                  | Semi-Quantitative Cell-Based Indirect Fluorescent Antibody   |
| Performed:                    | Wed  |
| Reported:                     | 1-8 days   |
| Note:                         | If Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by IFA with Reflex to Titer, Serum is positive, then an Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody Titer, IgG, Serum is reported. Additional charges apply. |
| CPT Codes:                    | 86255; if reflexed, add 86256  |
| New York DOH Approval Status: | This test is New York DOH approved.  |
| Interpretive Data:            |  |
| ALL                           |  |

Alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptor (AMPAR) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes AMPAR transfected cell lines for the detection and semiguantification semi-quantification of AMPAR lgG antibody.



Effective Date: August 21, 2023

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Less than 1:10